Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001

Inclusion criteria

• Having clinical diagnosis of primary membranous nephropathy, as verified by biopsy.
• Have positive anti-PLA2R autoantibody test results > 20 relative units (RU)/ml.
• During screening at least one testing of proteinuria must be >3.5 g/24h.
• Have nephrotic range proteinuria for at least 8 weeks prior to Day 1 and no improvement (<50% reduction) despite supportive therapy of ACE inhibitor or ARB unless contraindicated, for patients who have two tests of proteinuria during screening ≥8.0g/24h, the duration of nephrotic range proteinuria for at least 8 weeks is not required.

Exclusion criteria

• Non-primary membranous nephropathy or other condition affecting the kidney.
• eGFR at screening < 45 mL/min/1.73m2 or kidney function not stable .
• Uncontrolled hypertension .
• Serum albumin level at screening # 25g/l.
• Have received: B-cell targeted therapy except rituximab at any time;Rituximab and the biosimilars within 2 years (participants with rituximab treatment between 1 and 2 years prior to Day 1 are eligible if there is documented evidence of B-cell repopulation to >90% of Lower Limits of Normal Range.); Cyclophosphamide or Chlorambucil within 180 days;other immunosuppressive/immunomodulatory agents within 90 days;greater than 30mg/day prednisone or equivalence within 30 days.
• Acute or chronic infection,including positivity of tuberculosis infection test.
• Positive serology for TP,HIV, HBV, or HCV.
• Lab testing abnormality as: WBC< 3000/mm³, Lymphocyte < 1000/ mm³, neutrophil <1500/mm³, Hb < 80g/L, Platelet count <100×10e9/ L, Prothrombin time>1.5×ULN, Activated partial thromboplastin time ≥1.5×ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 1.5×ULN, alkaline phosphatase and bilirubin >1.5×ULN.
• Judged by the investigator that the participant is unlikely to comply with study procedures, restrictions, and requirements.